Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2/3 1

Status

Unknown 4Recruiting 3Completed 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Thoracic 4Other hematologic neoplasm 2Gastrointestinal 2CNS 2Tumor-Agnostic 1Myeloid 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3NSCLC 1Brain Neoplasms 1

Interventions

Carboplatin 132Cisplatin 129Pemetrexed 114Docetaxel 81Drug Therapy 62Gefitinib 57anlotinib 55Gemcitabine 55Erlotinib Hydrochloride 55Radiotherapy 48Bevacizumab 48pembrolizumab 47Paclitaxel 47Etoposide 44apatinib 42icotinib 41camrelizumab 39osimertinib 36Nivolumab 33Vinorelbine 31Radiosurgery 30sintilimab 29durvalumab 25aumolertinib 25endostar protein 24atezolizumab 22Endostatins 22toripalimab 19Blood Specimen Collection 19tislelizumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Tyrosine Kinase Inhibitors × Thoracic × Clear all
NCT03256981 2023-12-26

HALT

Institute of Cancer Research, United Kingdom

Phase 2/3 Unknown
113 enrolled
Thoracic

NSCLC

NCT03799094 2019-01-10

Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations

Clifford Hospital, Guangzhou, China

Phase 1/2 Unknown
150 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03424980 2018-02-08

A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors

Tang-Du Hospital

Unknown
200 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02906163 2016-09-19

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

SciClone Pharmaceuticals

Phase 1/2 Unknown
188 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡